A new study links semaglutide, the active ingredient in Ozempic and Wegovy, to a higher risk of hair loss, especially in ...

The annual meeting of the American Academy of Orthopaedic Surgeons was held from March 10 to 14 in San Diego, drawing ...

HealthDay News — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with better graft and patient survival among kidney transplant recipients with diabetes, according to a study ...

The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now ...

State lawmakers are considering expanding the types of obesity treatments covered by Nevada Medicaid, including approving ...

(HealthDay News) — Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize risks for complications, according to a study presented ...

The exorbitant costs of drugs like Wegovy — especially compared to other countries — have prompted some insurers to tighten ...

Weight loss from glucagon-like peptide 1 agonists clearly alleviates knee osteoarthritis pain, but other recently published data give pause regarding possible long-term adverse effects.

By screening people for eating disorders and disordered eating before these medications are prescribed, we can prevent ...

SAN DIEGO -- Two retrospective studies hinted at potential negative effects of GLP-1 receptor agonists for patients requiring ...

From findings about GLP-1s to spine surgery costs, Becker’s reported on nine key studies in spine and orthopedics since Feb. 13. 1. A study of cervical disc replacements in The Spine Journal found ...

Results presented here showed patients who had significant weight loss prior to total hip arthroplasty with use of a GLP-1 ...